Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Biagio Ricciuti
Jun 27, 2024, 20:12 |
Blog
Dana-Farber News - Biagio Ricciuti receives IASLC 2024 Young Investigator Grant
Dana-Farber News shared on X: "Congratulations to Biagio Ricciuti, who is a recipient of the IASLC…
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
May 31, 2024, 02:35 |
Blog
Biagio Ricciuti: Great conversation on the role of ICI in patients with NSCLC and driver mutations
Biagio Ricciuti shared a post by Narjust Florez on X, adding: , "I had a…
May 29, 2024, 09:25 |
Insight
Biagio Ricciuti: The association of automatically extracted body composition metrics with IO efficacy in mNSCLC
Biagio Ricciuti, recently posted on X: "Out in JAMA Oncology! Our effort to determine the…
May 12, 2024, 13:30 |
Blog
Biagio Ricciuti: Insightful discussions at Rome Lung 24
Biagio Ricciuti shared a post by Stephen Liu on X and added: "Had a great…
May 11, 2024, 12:13 |
Insight
Biagio Ricciuti: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: "Comprehensive mutational scanning of EGFR…
Apr 26, 2024, 10:00 |
Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 9, 2024, 13:33 |
Blog
Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''If you are at…
Apr 8, 2024, 23:10 |
Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
Apr 8, 2024, 14:35 |
Insight
Biagio Ricciuti: Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, posted on X: "Our collaborative effort to…
1
2
3
4
All:
36
Posts:
11 - 20
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube